Abstract 474P
Background
Good overall and disease-free survival for small primary lung cancers may be achieved with sublobar resections. These cancers presented as undiagnosed solitary lung nodule and may be difficult to localise intra-operatively due to their size or their ground glass nature, necessitating a greater anatomical resection. Our institution had adopted the use of image guided coil localisation since 2017 to aid the excision of such nodules. The localisation was performed on the same day just prior to the lung resection surgery. We aimed to share our experience with this technique.
Methods
We reviewed the outcomes of all patients who underwent surgical excision for undiagnosed solitary lung nodule between 2018 and 2021 and compared the efficacy with patients who had coil localisation and those who did not.
Results
182 consecutive patients were reviewed in our study. 36 patients (19.8%) underwent coil localisation whilst 146 patients (80.2%) did not. There was no significant difference in the pre-operative lung function between the 2 groups of patients. 88.5% of nodules were malignant and there was no significant difference in incidence between both groups (coil 91.7% vs no coil 87.7%, p = 0.368). Lung resection was performed via uniportal video assisted thoracoscopic (UVATS) in all coiling cases whilst 9 non-coiling cases (6.2%) had open thoracotomy. Patients who had coiling were more likely to underwent wedge resection than an anatomical resection (OR 2.14, 95% CI 1.62-2.82, p < 0.001).The conversion rate was lower in patients who had underwent coil localisation (OR 0.72, 95% CI 0.27-1.98) but this was not statistically significant (p = 0.367). All patients who underwent coil localisation reported clear margins on final histology. Patient who underwent coil localisation had a shorter length of stay (mean 3.44 +/- 2.92 days) than those who did not (mean 4.07 +/- 3.21 days) (p = 0.290). There was no significant difference in complications between both group of patients.
Conclusions
Both diagnostic and cure can be achieved via UVATS wedge resection with the aid of coil localisation. Our study demonstrated it as a safe and effective method of managing suspicious small primary lung cancers presenting as a small solitary lung nodule.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract